Peter Paradiso

Summary

Affiliation: Wyeth Research
Country: USA

Publications

  1. ncbi Establishing government-operated vaccine programs: an industry perspective
    Peter R Paradiso
    Wyeth Vaccines, Collegeville, PA 19426, USA
    Clin Infect Dis 42:S118-20. 2006
  2. ncbi Essential criteria for evaluation of pneumococcal conjugate vaccine candidates
    Peter Paradiso
    Wyeth Vaccines, Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, PA 19426, USA
    Vaccine 27:C15-8. 2009
  3. ncbi Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies
    George R Siber
    Wyeth Vaccines Research, Pearl River, New York, USA
    Vaccine 25:3816-26. 2007
  4. ncbi Recent progress in the development of vaccines for infants and children
    E David G McIntosh
    Wyeth, Huntercombe Lane South, Taplow, Berkshire SL6 0PH, Maidenhead, UK
    Vaccine 21:601-4. 2003
  5. ncbi Strengthening the supply of routinely recommended vaccines in the United States: recommendations from the National Vaccine Advisory Committee
    Jeanne M Santoli
    Centers for Disease Control and Prevention, Atlanta, GA, USA
    JAMA 290:3122-8. 2003

Collaborators

Detail Information

Publications5

  1. ncbi Establishing government-operated vaccine programs: an industry perspective
    Peter R Paradiso
    Wyeth Vaccines, Collegeville, PA 19426, USA
    Clin Infect Dis 42:S118-20. 2006
    ..A secure and stable vaccine supply is best built by establishing the importance and value of our vaccine programs, which would, in turn, provide incentives to manufacturers to build capacity and inventories...
  2. ncbi Essential criteria for evaluation of pneumococcal conjugate vaccine candidates
    Peter Paradiso
    Wyeth Vaccines, Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, PA 19426, USA
    Vaccine 27:C15-8. 2009
    ..35 microg/mL for serotypes shared with PCV7 and >96% for six additional serotypes...
  3. ncbi Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies
    George R Siber
    Wyeth Vaccines Research, Pearl River, New York, USA
    Vaccine 25:3816-26. 2007
    ..35 microg/ml to 0.32 microg/ml. These data support retaining the 0.35 microg/ml minimum protective concentration recommended by WHO for assessing the efficacy of pneumococcal conjugate vaccines in infants...
  4. ncbi Recent progress in the development of vaccines for infants and children
    E David G McIntosh
    Wyeth, Huntercombe Lane South, Taplow, Berkshire SL6 0PH, Maidenhead, UK
    Vaccine 21:601-4. 2003
    ..This brief overview examines the following: Streptococcus pneumoniae, Neisseria meningitidis, varicella zoster, measles, rotavirus, HIV, influenza, "emerging" viral infections and cancer...
  5. ncbi Strengthening the supply of routinely recommended vaccines in the United States: recommendations from the National Vaccine Advisory Committee
    Jeanne M Santoli
    Centers for Disease Control and Prevention, Atlanta, GA, USA
    JAMA 290:3122-8. 2003
    ..Strategies requiring further study include evaluation of appropriate financial incentives to manufacturers and streamlining the regulatory process without compromising safety or efficacy...